Goldman Sachs Maintains Sell on TG Therapeutics, Raises Price Target to $16
Portfolio Pulse from Benzinga Newsdesk
Goldman Sachs analyst Corinne Jenkins maintains a 'Sell' rating on TG Therapeutics (NASDAQ:TGTX), but raises the price target from $10 to $16.
July 24, 2023 | 12:26 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Despite the 'Sell' rating maintained by Goldman Sachs, the raised price target from $10 to $16 indicates a potential upside for TG Therapeutics.
The 'Sell' rating suggests that Goldman Sachs expects TGTX's stock price to underperform. However, the raised price target from $10 to $16 indicates that they see some potential upside. This could lead to mixed market reactions, hence the neutral score.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100